LANREOTIDE ACETATE
| Brand name | LANREOTIDE ACETATE |
|---|---|
| Active ingredient | LANREOTIDE ACETATE |
| Strength | EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | September 2026 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| CGT | March 2027 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.